Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection
NCT ID: NCT04407143
Last Updated: 2026-02-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1980 participants
OBSERVATIONAL
2020-04-15
2022-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main objective of the study is th description of the characteristics and evolution of patients with lung cancer who have acquired COVID-19 infection.
For the identification of patients who contract COVID-19 infection, the IgG+ blood test by ELISA method will be used.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anti-SARS-COV2 Vaccination Study in Lung Cancer Patients
NCT05009030
The Role of Interventional Pulmonology, Microbiota and Immune Response in the Patient With Lung Cancer
NCT05164445
Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy.
NCT04720339
LunG and Melanoma canceR pAtients coVId19 Disease (GRAVID)
NCT04344002
Tumor Associated Neutrophils as a Biomarker of Chemo-immunotherapy Response in Locally Advanced Non-small Cell Lung Cancer : a Model Based on Neoadjuvant Strategy
NCT06974097
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will be extended to all the sites of the Spanish Lung Cancer Group, more than 170 centers and 500 professionals, and it is expected that around 1,500 IgG tests will be carried out.
The study has three phases:
The scope of phase I is the identification of acquired immunity (IgG) in patients with lung cancer, whether or not they have presented symptoms of having suffered from COVID19. In addition, the description of the characteristics and evolution of patients with lung cancer who have contracted COVID-19 infection will be carried out.
For the identification of patients who contract COVID-19 infection, the IgG+ test in blood will be used by ELISA method.
The scope of phase II is the confirmation of the presence of antibodies (IgG) in patients who tested positive in Phase I of the study a few weeks after the first diagnosis made through the SOLID study.
The scope of phase III is the confirmation of the presence of antibodies (IgG) in patients with lung cancer who have been vaccinated with any of the available and authorized vaccines for SARS-COV2 and 6 months after said administration.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
lung cancer+COVID-19
Lung cancer patients infected by COVID-19
IgG test
IgG+ blood test by ELISA method.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IgG test
IgG+ blood test by ELISA method.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age ≥ 18
3. Patients who have signed the informed consent for this study
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundación GECP
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mariano Provencio, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Puerta de Hierro de Majadahonda de Madrid
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Complejo Hospitalario de A Coruña
A Coruña, A Coruña, Spain
Hospital General Universitario de Elche
Elche, Alicante, Spain
Hospital Clínic de Barcelona
Barcelona, Barcelona, Spain
ICO Hospitalet
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitario de Burgos
Burgos, Burgos, Spain
Hospital Universitario Reina Sofía
Córdoba, Córdoba, Spain
Hospital Dr. Josep Trueta
Girona, Girona, Spain
Hospital Universitario Insular de Gran canaria
Las Palmas de Gran Canaria, Gran Canaria, Spain
Complejo Hospitalario de Jaén
Jaén, Jaén, Spain
Hospital Universitario Fundación Jiménez Díaz
Madrid, Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Madrid, Spain
Hospital Universitario La Paz
Madrid, Madrid, Spain
Hospital Puerta de Hierro
Madrid, Madrid, Spain
Clínica Universidad de Navarra
Madrid, Madrid, Spain
Hospital de Sanchinarro
Madrid, Madrid, Spain
Hospital Severo Ochoa
Madrid, Madrid, Spain
Hospital Universitario Infanta Cristina
Madrid, Madrid, Spain
Hospital Universitario de Torrejón
Torrejón, Madrid, Spain
Hospital Universitario Son Llàtzer
Palma de Mallorca, Mallorca, Spain
Hospital General Universitario de Málaga
Málaga, Málaga, Spain
Complexo Hospitalario Universitario de Vigo
Vigo, Pontevedra, Spain
Hospital Virgen del Rocío
Seville, Sevilla, Spain
Hospital Universitario Nuestra Señora de Candelaria
Santa Cruz de Tenerife, Tenerife, Spain
Hospital Universitari i Politécnic La Fe
Valencia, Valencia, Spain
Hospital Clínico Universitario de Valencia
Valencia, Valencia, Spain
Hospital General de Valencia
Valencia, Valencia, Spain
Hospital Universitario Dr. Peset
Valencia, Valencia, Spain
Hospital Clínico Universitario de Valladolid
Valladolid, Valladolid, Spain
Hospital La Esperanza
A Coruña, , Spain
Hospital Universitario de Ferrol
A Coruña, , Spain
Hospital Virgen de los Lirios
Alicante, , Spain
Hospital Germans Trias i Pujol
Badalona, , Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, , Spain
Hospital Universitari Dexeus
Barcelona, , Spain
Hospital Universitario Cruces
Bilbao, , Spain
Hospital Universitario Puerta del Mar
Cadiz, , Spain
Hospital Universitario Puerto Real
Cadiz, , Spain
Hospital Universitario San Pedro de Alcántara
Cáceres, , Spain
Hospital General La Mancha Centro
Ciudad Real, , Spain
Hospital Universitario de Vinalopó
Elche, , Spain
Hospital Universitario de Guadalajara
Guadalajara, , Spain
Complejo Asistencial Universitario de León
León, , Spain
Hospital universitari Arnau de Vilanova
Lleida, , Spain
Hospital San Pedro
Logroño, , Spain
Hospital Universitario Lucus Augusti
Lugo, , Spain
Hospital General Universitario Gregorio Marañón
Madrid, , Spain
Hospital Universitario de Móstoles
Madrid, , Spain
Hospital Universitario del Henares
Madrid, , Spain
Hospital Universitario Fundación Alcorcón
Madrid, , Spain
Hospital Universitario Infanta Leonor
Madrid, , Spain
Hospital Universitario Infanta Sofía
Madrid, , Spain
Hospital Universitario Príncipe de Asturias
Madrid, , Spain
Hospital Costa del Sol
Málaga, , Spain
Complejo Hospitalario Universitario de Ourense Santa María Nai
Ourense, , Spain
Hospital Universitario Son Espases
Palma de Mallorca, , Spain
Clínica Universidad de Navarra
Pamplona, , Spain
Complejo Hospitalario de Navarra
Pamplona, , Spain
Hospital Universitario Sant Joan de Reus
Reus, , Spain
Hospital Universitario de Salamanca
Salamanca, , Spain
Hospital Universitario de Canarias
Santa Cruz de Tenerife, , Spain
Hospital General de Segovia
Segovia, , Spain
Hospital Sant Pau i Santa Tecla
Tarragona, , Spain
Hospital Arnau de Vilanova
Valencia, , Spain
Hospital de Manises
Valencia, , Spain
Hospital General Universitario de Valencia
Valencia, , Spain
Hospital Lluís Alcanyís
Valencia, , Spain
Hospital Universitario Río Ortega
Valladolid, , Spain
Complejo Hospitalario Zamora
Zamora, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Provencio M, Estival A, Franco F, Lopez-Vivanco G, Saigi M, Arasanz H, Diz P, Carcereny E, Garcia J, Aguado C, Mosquera J, Iruarrizaga E, Majem M, Bosch-Barrera J, Mielgo-Rubio X, Guirado M, Juan-Vidal O, Blasco A, Lucia Gozalvez C, Del Barrio A, De Portugal T, Lopez-Martin A, Serrano G, Campos B, Rubio J, Catot S, Esteban B, Marti-Ciriquian JL, Del Barco E, Calvo V; Spanish Lung Cancer Group (SLGC/GECP). Immunogenicity of COVID-19 vaccines in lung cancer patients. Lung Cancer. 2023 Oct;184:107323. doi: 10.1016/j.lungcan.2023.107323. Epub 2023 Aug 9.
Provencio M, Rodriguez-Abreu D, Ortega AL, Serrano G, Aguado C, Franco F, Gutierrez V, Lopez Vivanco G, Guirado M, Benitez G, Estival A, Calvo V, Jimenez B, Arasanz H, Coves J, Majem M, Massuti B, Vazquez S, Juan-Vidal O, Collazo-Lorduy A, Gozalvez CL, Del Barco E, Rosero A, Bosch-Barrerra J, Moreno MA, Mielgo-Rubio X, Villa JC, Lopez-Martin A, Cordoba JF, de Asis Aparisi F, Zafra M, Mosquera J, Perez Altozano J, Nadal E, Catot S, Balsalobre J, de Portugal T, Martin P, Cuesta de Juan S, Cobo M. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study. Transl Lung Cancer Res. 2022 Jan;11(1):53-63. doi: 10.21037/tlcr-21-504.
Related Links
Access external resources that provide additional context or updates about the study.
Web page of the sponsor where users can find more information about Fundación GECP studies
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GECP 20/04_SOLID
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.